Publicaciones en colaboración con investigadores/as de Hospital Universitario La Fe (21)

2021

  1. Circadian PERformance in breast cancer: a germline and somatic genetic study of PER3 VNTR polymorphisms and gene co-expression

    npj Breast Cancer, Vol. 7, Núm. 1

2018

  1. Outcomes of single versus double hormone receptor–positive breast cancer. A GEICAM/9906 sub-study

    European Journal of Cancer, Vol. 94, pp. 199-205

  2. Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy

    Clinical and Translational Oncology, Vol. 20, Núm. 12, pp. 1548-1556

2016

  1. Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile

    Current Cancer Drug Targets, Vol. 16, Núm. 5, pp. 415-428

  2. Non-canonical NF-κB pathway activation predicts outcome in borderline oestrogen receptor positive breast carcinoma

    British Journal of Cancer, Vol. 115, Núm. 3, pp. 322-331

2015

  1. Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: Results from the GEICAM/2003-10 study

    Journal of Clinical Oncology, Vol. 33, Núm. 32, pp. 3788-3795

2014

  1. Predicting response and survival in chemotherapy-treated triple-negative breast cancer

    British Journal of Cancer, Vol. 111, Núm. 8, pp. 1532-1541

2010

  1. Adjuvant docetaxel for high-risk, node-negative breast cancer

    New England Journal of Medicine, Vol. 363, Núm. 23, pp. 2200-2210

  2. Practical prognostic index for patients with metastatic recurrent breast cancer: Retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register

    Breast Cancer Research and Treatment, Vol. 122, Núm. 2, pp. 591-600

2009

  1. Guidelines for HER2 testing in breast cancer: A national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM)

    Clinical and Translational Oncology, Vol. 11, Núm. 6, pp. 363-375

2008

  1. Metástasis en iris de un carcinoma de mama: ¿Modifica el tratamiento la historia natural de la enfermedad?

    Anales de Medicina Interna, Vol. 25, Núm. 4, pp. 178-180

  2. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer

    Journal of the National Cancer Institute, Vol. 100, Núm. 11, pp. 805-814

  3. Time-to-progression in breast cancer: A stratification model for clinical trials

    Breast, Vol. 17, Núm. 3, pp. 239-244

2007

  1. Role of MTHFR (677, 1298) haplotype in the risk of developing secondary leukemia after treatment of breast cancer and hematological malignancies

    Leukemia, Vol. 21, Núm. 7, pp. 1413-1422

2006

  1. The «El Álamo» project (1990-1997): Two consecutive hospital-based studies of breast cancer outcomes in Spain

    Clinical and Translational Oncology, Vol. 8, Núm. 7, pp. 508-518

2005

  1. Improvement of breast cancer relapse prediction in high risk intervals using artificial neural networks

    Breast Cancer Research and Treatment, Vol. 94, Núm. 3, pp. 265-272

1997

  1. Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and their relation to estradiol receptor (ER) status

    Clinica Chimica Acta, Vol. 262, Núm. 1-2, pp. 99-119

1994

  1. Estradiol receptors in combination with neu or myc oncogene amplifications might define new subtypes of breast cancer

    Clinica Chimica Acta, Vol. 229, Núm. 1-2, pp. 107-122

1993

  1. Epidermal growth factor in human breast cancer, endometrial carcinoma and lung cancer. Its relationship to epidermal growth factor receptor, estradiol receptor and tumor TNM

    Clinica Chimica Acta, Vol. 215, Núm. 1, pp. 51-63

1992

  1. Aromatase activity and estradiol in human breast cancer: Its relationship to estradiol and epidermal growth factor receptors and to tumor-node-metastasis staging

    Journal of Clinical Oncology, Vol. 10, Núm. 3, pp. 438-446